DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial 

DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial 

Abstract Background Despite treatment with highly effective antimalarial drugs, malaria annually claims the lives of over half a million children under 5-years of age in sub-Saharan Africa. Cerebral malaria (CM), defined as Plasmodium falciparum infection with coma, is the severe malaria syndrome wi...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Nginache Nampota-Nkomba, Osward M. Nyirenda, Jane Mallewa, Yamikani Chimalizeni, Nettie Dzabala, Michael P. Fay, Mathangi Gopalakrishnan, Matthew B. Laurens, Nicole F. O’Brien, Louis H. Miller, Susan K. Pierce, Brittany A. Riggle, Douglas G. Postels
التنسيق: مقال
اللغة:English
منشور في: BMC 2024-01-01
سلاسل:Trials
الموضوعات:
6-Diazo-5-oxo-L-norleucine
DON
Glutamine antagonist
Cerebral malaria
Malaria
Plasmodium falciparum
الوصول للمادة أونلاين:https://doi.org/10.1186/s13063-023-07808-w

الانترنت

https://doi.org/10.1186/s13063-023-07808-w

مواد مشابهة